Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Myelodysplastic Syndromes 40Multiple Myeloma 34Lymphoma 32Leukemia 28Lymphoma, Non-Hodgkin 27Leukemia, Lymphocytic, Chronic, B-Cell 24Hodgkin Disease 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20Hematologic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Primary Myelofibrosis 11Neoplasms, Plasma Cell 10Leukemia, Myelomonocytic, Chronic 10Lymphoma, Follicular 9Graft vs Host Disease 9Myeloproliferative Disorders 8Neuroblastoma 7Leukemia, Myelomonocytic, Juvenile 7Lymphoma, Mantle-Cell 6Breast Neoplasms 6Recurrence 5Neoplasms 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Biphenotypic, Acute 5Wilms Tumor 4Rhabdoid Tumor 4Polycythemia Vera 4Lymphoma, T-Cell 4

Interventions

fludarabine phosphate 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Cyclophosphamide 7Mycophenolic Acid 6Lenalidomide 6Dexamethasone 6Tacrolimus 5Bortezomib 4Sirolimus 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2Calcium Dobesilate 2Antilymphocyte Serum 2Allopurinol 2talquetamab 1sargramostim 1pomalidomide 1montanide ISA 51 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Plasma Cell × Stem Cell Transplantation × Clear all
NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00615589 2016-04-04

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

University of Michigan Rogel Cancer Center

Phase 2 Terminated
22 enrolled 9 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡